Carisoprodol (INN)
Carisoprodol (INN) is listed in Annex II as a prohibited substance for cosmetic products placed on the EU market.
Chemical identity and properties
Carisoprodol
Carisoprodol is a carbamate ester that is the mono-N-isopropyl derivative of meprobamate (which is a significant metabolite). Carisoprodol interrupts neuronal communication within the reticular formation and spinal cord, resulting in sedation and alteration in pain perception. It is used as a muscle relaxant in the symptomatic treatment of musculoskeletal conditions associated with painful muscle spasm. It has a role as a muscle relaxant. — ChEBI
- IUPAC name
- [2-(carbamoyloxymethyl)-2-methylpentyl] N-propan-2-ylcarbamate
- Molecular formula
- C12H24N2O4
- Molecular weight
- 260.33 g/mol
- Exact mass
- 260.17360725 Da
- XLogP3
- 1.9
- Topological polar surface area
- 90.7 Ų
- Hydrogen-bond donors
- 2
- Hydrogen-bond acceptors
- 4
- Covalent units
- 1
- Defined stereocentres
- 0
Also known as
16 more reported names
External database identifiers
- ChEBI:CHEBI:3419
- ChEMBL:CHEMBL1233
- EPA DTXSID:DTXSID8024733
- PubMed:27758843
- PubMed:23040985
- PubMed:22963024
- PubMed:22939305
- PubMed:22687764
- PubMed:22548189
- PubMed:22527345
- PubMed:22511696
- PubMed:22492384
- PubMed:22417839
- PubMed:22417833
- PubMed:22362883
Retrieved from NIH PubChem on 2026-08-31 by checksum-valid CAS matching. Chemical properties do not replace the regulatory decision on this page.
Record details
Chemical name
Carisoprodol (INN)
Chemical / IUPAC name
Carbamic acid, isopropyl-, 2-(hydroxymethyl)-2-methylpentyl ester carbamate (ester)
Regulatory information
Key data
Related records for Carisoprodol (INN)
Direct matches are limited for this record, so nearby entries from Annex II are shown as well.
3,4-Dihydro-2-methoxy-2-methyl-4-phenyl-2H,5H-pyrano[3,2-c]-[1]benzopyran-5-one (cyclocoumarol)
Phenmetrazine (INN), its derivatives and salts
What Annex II means for Carisoprodol (INN)
Carisoprodol (INN) is listed as a prohibited substance under Annex II of EU Cosmetics Regulation 1223/2009 and must not be intentionally added. Article 17 separately addresses unintended small quantities that are technically unavoidable under good manufacturing practice and compatible with the Article 3 safety requirement.
Formulators must screen their ingredients and raw materials to ensure none contain this substance. Suppliers should provide documentation confirming absence when requested.
The page also surfaces 12 related annex records with overlapping identifiers, annex logic or naming patterns.
Compliance checklist
- Verify this substance is absent from all raw materials and finished formulations.
- Request absence confirmation or CoA from raw material suppliers.
- Document the screening result in the Product Information File (PIF).
Frequently asked questions
Source note for Annex II record Carisoprodol (INN)
This page summarizes one Annex II record for Carisoprodol (INN) from public European Commission cosmetic materials and adds linked inventory or identifier matches when available.
Use this record page to review Annex II conditions for Carisoprodol (INN), but confirm any final regulatory decision against the current official annex wording and source files.
Tools & next steps
Check your formula
Paste a full INCI list to detect Carisoprodol (INN) and other flagged EU annex records in one pass.
INCI CheckerCompare entries
Compare Carisoprodol (INN) side by side with another annex record to review differences in restrictions, concentrations and annex placement.
CompareBrowse the annex
See all records in Annex II and compare regulatory conditions across substances in this annex.
Open Annex II